Minerva Neurosciences, Inc. (NERV) saw a massive surge of 339.33% to $11.73 after securing a $200 million financing deal for its schizophrenia drug candidate, roluperidone. The agreement includes $80 million upfront, $80 million through Tranche A warrants, and $40 million via milestone-based Tranche B warrants. This funding will support a confirmatory Phase 3 trial, NDA resubmission, and potential U.S. commercial launch. NERV opened at $3.02, hit a high of $12.15, and a low of $2.97, with trading volume exceeding 70 million shares. The stock’s 52-week range is $1.03 – $12.15.

Read more at Nasdaq: Minerva Neurosciences Jumps 339% On $200M Financing Agreement